FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Junko Okabe-Kado

Research Profile

Physiology

Chemicals & Drugs

Disorders

Anatomy

Living Beings

Mouse

Co-author Network

Publications

TOP 3
Takashi Kasukabe; Nobuo Kato; Junko Okabe-Kado; Yu Haranosono; Yoshio Honma
Inhibition of rapamycin-induced Akt phosphorylation by cotylenin A correlates with their synergistic growth inhibition of cancer cells.
Junko Okabe-Kado; Takashi Kasukabe; Yasuhiko Kaneko
Extracellular NM23 Protein as a Therapeutic Target for Hematologic Malignancies.
Yuki Hagiwara; Takashi Kasukabe; Yasuhiko Kaneko; Nozomi Niitsu; Junko Okabe-Kado
Ellagic acid, a natural polyphenolic compound, induces apoptosis and potentiates retinoic acid-induced differentiation of human leukemia HL-60 cells.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Junko Okabe-Kado (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Takashi Kasukabe; Nobuo Kato; Junko Okabe-Kado; Yu Haranosono; Yoshio Honma
Inhibition of rapamycin-induced Akt phosphorylation by cotylenin A correlates with their synergistic growth inhibition of cancer cells.
International journal of oncology 2013;42(2):767-75.
2012: Junko Okabe-Kado; Takashi Kasukabe; Yasuhiko Kaneko
Extracellular NM23 Protein as a Therapeutic Target for Hematologic Malignancies.
Advances in hematology 2012;2012():879368.
2010: Yuki Hagiwara; Takashi Kasukabe; Yasuhiko Kaneko; Nozomi Niitsu; Junko Okabe-Kado
Ellagic acid, a natural polyphenolic compound, induces apoptosis and potentiates retinoic acid-induced differentiation of human leukemia HL-60 cells.
International journal of hematology 2010;92(1):136-43.
2009: Junko Okabe-Kado; Takashi Kasukabe; Yoshio Honma; Hirofumi Kobayashi; Nobuo Maseki; Yasuhiko Kaneko
Extracellular NM23 protein promotes the growth and survival of primary cultured human acute myelogenous leukemia cells.
Cancer science 2009;100(10):1885-94.
2009: Junko Okabe-Kado; Takashi Kasukabe; Yoshio Honma; Hirofumi Kobayashi; Nobuo Maseki; Yasuhiko Kaneko
Extracellular NM23-H1 protein inhibits the survival of primary cultured normal human peripheral blood mononuclear cells and activates the cytokine production.
International journal of hematology 2009;90(2):143-52.
2008: Takashi Kasukabe; Junko Okabe-Kado; Yoshio Honma
Cotylenin A, a new differentiation inducer, and rapamycin cooperatively inhibit growth of cancer cells through induction of cyclin G2.
Cancer science 2008;99(8):1693-8.
2005: Junko Okabe-Kado; Takashi Kasukabe; Yoshio Honma; Ryoji Hanada; Akira Nakagawara; Yasuhiko Kaneko
Clinical significance of serum NM23-H1 protein in neuroblastoma.
Cancer science 2005;96(10):653-60.
2005: Takashi Kasukabe; Junko Okabe-Kado; Nobuo Kato; Takeshi Sassa; Yoshio Honma
Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts.
Breast cancer research : BCR 2005;7(6):R1097-110.
2004: Nozomi Niitsu; Hirokazu Nakamine; Masataka Okamoto; Hiroko Akamatsu; Masaaki Higashihara; Yoshio Honma; Junko Okabe-Kado; Masami Hirano
Clinical significance of intracytoplasmic nm23-H1 expression in diffuse large B-cell lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(7):2482-90.
2004: Akihiro Yokoyama; Takuya Yamashita; Eisuke Shiozawa; Atsuko Nagasawa; Junko Okabe-Kado; Tsuyoshi Nakamaki; Shigeru Tomoyasu; Fumihiko Kimura; Kazuo Motoyoshi; Yoshio Honma; Takashi Kasukabe
MmTRA1b/phospholipid scramblase 1 gene expression is a new prognostic factor for acute myelogenous leukemia.
Leukemia research 2004;28(2):149-57.
2003: Nozomi Niitsu; Hirokazu Nakamine; Masataka Okamoto; Hiroko Akamatsu; Yoshio Honma; Masaaki Higashihara; Junko Okabe-Kado; Masami Hirano
Expression of nm23-H1 is associated with poor prognosis in peripheral T-cell lymphoma.
British journal of haematology 2003;123(4):621-30.
2003: Yuri Yamamoto-Yamaguchi; Junko Okabe-Kado; Takashi Kasukabe; Yoshio Honma
Induction of apoptosis by combined treatment with differentiation-inducing agents and interferon-alpha in human lung cancer cells.
Anticancer research 2003;23(3B):2537-47.
2003: Nozomi Niitsu; Masataka Okamoto; Y Honma; Hirokazu Nakamine; Jun-ichi Tamaru; Shigeo Nakamura; T Yoshino; Masaaki Higashihara; Masami Hirano; Junko Okabe-Kado
Serum levels of the nm23-H1 protein and their clinical implication in extranodal NK/T-cell lymphoma.
Leukemia 2003;17(5):987-90.
2003: Junko Okabe-Kado; Takashi Kasukabe
Physiological and pathological relevance of extracellular NM23/NDP kinases.
Journal of bioenergetics and biomembranes 2003;35(1):89-93.
2003: Nozomi Niitsu; Yoshio Honma; K Iijima; T Takagi; Masaaki Higashihara; U Sawada; Junko Okabe-Kado
Clinical significance of nm23-H1 proteins expressed on cell surface in non-Hodgkin's lymphoma.
Leukemia 2003;17(1):196-202.
2002: Junko Okabe-Kado; Takashi Kasukabe; Yoshio Honma
Expression of cell surface NM23 proteins of human leukemia cell lines of various cellular lineage and differentiation stages.
Leukemia research 2002;26(6):569-76.
2002: Tsuyoshi Nakamaki; Junko Okabe-Kado; Yuri Yamamoto-Yamaguchi; Ken ichiro Hino; Shigeru Tomoyasu; Yoshio Honma; Takashi Kasukabe
Role of MmTRA1b/phospholipid scramblase1 gene expression in the induction of differentiation of human myeloid leukemia cells into granulocytes.
Experimental hematology 2002;30(5):421-9.
2002: Junko Okabe-Kado
Serum nm23-H1 protein as a prognostic factor in hematological malignancies.
Leukemia & lymphoma 2002;43(4):859-67.
2001: Yuri Yamamoto-Yamaguchi; Junko Okabe-Kado; Takashi Kasukabe; Yoshio Honma
Induction of differentiation of human myeloid leukemia cells by immunosuppressant macrolides (rapamycin and FK506) and calcium/calmodulin-dependent kinase inhibitors.
Experimental hematology 2001;29(5):582-8.
2001: Nozomi Niitsu; Masataka Okamoto; Junko Okabe-Kado; T Takagi; T Yoshida; S Aoki; Yoshio Honma; Masami Hirano
Serum nm23-H1 protein as a prognostic factor for indolent non-Hodgkin's lymphoma.
Leukemia 2001;15(5):832-9.
2001: Nozomi Niitsu; Junko Okabe-Kado; M Okamoto; T Takagi; T Yoshida; S Aoki; M Hirano; Yoshio Honma
Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma.
Blood 2001;97(5):1202-10.
2001: Yoshio Honma; Yuki Ishii; Takashi Kasukabe; Junko Okabe-Kado; Yuri Yamamoto-Yamaguchi; T Kakegawa; A Awaya
Induction of differentiation of human myeloid leukemia cells by novel synthetic neurotrophic pyrimidine derivatives.
Experimental hematology 2001;29(2):194-201.
2000: Nozomi Niitsu; Yuri Yamamoto-Yamaguchi; Takashi Kasukabe; Junko Okabe-Kado; M Umeda; Yoshio Honma
Antileukemic efficacy of 2-deoxycoformycin in monocytic leukemia cells.
Blood 2000;96(4):1512-6.
2000: Nozomi Niitsu; Junko Okabe-Kado; M Nakayama; Naoki Wakimoto; Akiko Sakashita; Nobuo Maseki; Kazuo Motoyoshi; M Umeda; Yoshio Honma
Plasma levels of the differentiation inhibitory factor nm23-H1 protein and their clinical implications in acute myelogenous leukemia.
Blood 2000;96(3):1080-6.
2000: Nozomi Niitsu; Takashi Kasukabe; A Yokoyama; Junko Okabe-Kado; Yuri Yamamoto-Yamaguchi; M Umeda; Yoshio Honma
Anticancer derivative of butyric acid (Pivalyloxymethyl butyrate) specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activity.
Molecular pharmacology 2000;58(1):27-36.
1999: Nozomi Niitsu; Junko Okabe-Kado; Takashi Kasukabe; Yuri Yamamoto-Yamaguchi; M Umeda; Yoshio Honma
Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma.
Blood 1999;94(10):3541-50.
1999: Y Kanatani; Takashi Kasukabe; Junko Okabe-Kado; Yuri Yamamoto-Yamaguchi; N Nagata; K Motoyoshi; Yoshio Honma
Role of CD14 expression in the differentiation-apoptosis switch in human monocytic leukemia cells treated with 1alpha,25-dihydroxyvitamin D3 or dexamethasone in the presence of transforming growth factor beta1.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1999;10(10):705-12.
1998: Junko Okabe-Kado; Takashi Kasukabe; Yoshio Honma
Differentiation inhibitory factor Nm23 as a prognostic factor for acute myeloid leukemia.
Leukemia & lymphoma 1998;32(1-2):19-28.
1998: Takashi Kasukabe; H Kobayashi; Y Kaneko; Junko Okabe-Kado; Yoshio Honma
Identity of human normal counterpart (MmTRA1b) of mouse leukemogenesis-associated gene (MmTRA1a) product as plasma membrane phospholipid scramblase and chromosome mapping of the human MmTRA1b/phospholipid scramblase gene.
Biochemical and biophysical research communications 1998;249(2):449-55.
1998: Yoshio Honma; H Tobe; M Makishima; A Yokoyama; Junko Okabe-Kado
Induction of differentiation of myelogenous leukemia cells by humulone, a bitter in the hop.
Leukemia research 1998;22(7):605-10.
1998: Naoki Wakimoto; A Yokoyama; Junko Okabe-Kado; Naokazu Nagata; Kazuo Motoyoshi; Yoshio Honma
Combined analysis of differentiation inhibitory factor nm23-H1 and nm23-H2 as prognostic factors in acute myeloid leukaemia.
British journal of cancer 1998;77(12):2298-303.
1998: Naoki Wakimoto; A Yokoyama; Y Mukai; Naruo Kuwada; Takuya Yamashita; Takuya Matsumura; Yukitsugu Nakamura; Y Kanatani; Naokazu Nagata; Junko Okabe-Kado; Yoshio Honma; Kazuo Motoyoshi
Elevated expression of differentiation inhibitory factor nm23 mRNA in monoblastic crisis of a patient with chronic myelogenous leukemia.
International journal of hematology 1998;67(3):313-8.
1998: A Yokoyama; Junko Okabe-Kado; Naoki Wakimoto; H Kobayashi; Akiko Sakashita; Nobuo Maseki; Tsuyoshi Nakamaki; K i Hino; Shigeru Tomoyasu; N Tsuruoka; Kazuo Motoyoshi; Naokazu Nagata; Yoshio Honma
Evaluation by multivariate analysis of the differentiation inhibitory factor nm23 as a prognostic factor in acute myelogenous leukemia and application to other hematologic malignancies.
Blood 1998;91(6):1845-51.
1998: M Makishima; Junko Okabe-Kado; Yoshio Honma
Growth inhibition and differentiation induction in human monoblastic leukaemia cells by 1alpha-hydroxyvitamin D derivatives and their enhancement by combination with hydroxyurea.
British journal of cancer 1998;77(1):33-9.
1997: Takashi Kasukabe; Junko Okabe-Kado; Yoshio Honma
TRA1, a novel mRNA highly expressed in leukemogenic mouse monocytic sublines but not in nonleukemogenic sublines.
Blood 1997;89(8):2975-85.
1996: A Yokoyama; Junko Okabe-Kado; Akiko Sakashita; Nobuo Maseki; Y Kaneko; K Hino; Shigeru Tomoyasu; N Tsuruoka; Takashi Kasukabe; Y Honma
Differentiation inhibitory factor nm23 as a new prognostic factor in acute monocytic leukemia.
Blood 1996;88(9):3555-61.
1996: A Yokoyama; Junko Okabe-Kado; Y Uehara; T Oki; S Tomoyasu; N Tsuruoka; Yoshio Honma
Angelmicin B, a new inhibitor of oncogenic signal transduction, inhibits growth and induces myelomonocytic differentiation of human myeloid leukemia HL-60 cells.
Leukemia research 1996;20(6):491-7.
1996: Y Kanatani; Takashi Kasukabe; Junko Okabe-Kado; S Hayashi; Yuri Yamamoto-Yamaguchi; Kazuo Motoyoshi; Naokazu Nagata; Yoshio Honma
Transforming growth factor beta and dexamethasone cooperatively enhance c-jun gene expression and inhibit the growth of human monocytoid leukemia cells.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1996;7(2):187-96.
1996: S Sato; S Tomoyasu; Junko Okabe-Kado; M Hozumi; N Tsuruoka; S Nakai; M Adachi; Yoshio Honma
Induction of differentiation and enhancement of vincristine sensitivity of human erythroleukemia HEL cells by vesnarinone, a positive inotropic agent.
Experimental hematology 1996;24(1):37-42.
1995: Junko Okabe-Kado; Takashi Kasukabe; H Baba; T Urano; H Shiku; Yoshio Honma
Inhibitory action of nm23 proteins on induction of erythroid differentiation of human leukemia cells.
Biochimica et biophysica acta 1995;1267(2-3):101-6.
1995: Junko Okabe-Kado; Takashi Kasukabe; M Hozumi; Yoshio Honma; N Kimura; H Baba; T Urano; H Shiku
A new function of Nm23/NDP kinase as a differentiation inhibitory factor, which does not require it's kinase activity.
FEBS letters 1995;363(3):311-5.
1994: M Hayashi; Junko Okabe-Kado; M Hozumi
Flow-cytometric analysis of in vivo induction of differentiation of WEHI-3B myelomonocytic leukemia cells by recombinant granulocyte colony-stimulating factor.
Experimental hematology 1994;22(4):393-8.
1994: Takashi Kasukabe; Junko Okabe-Kado; M Hozumi; Yoshio Honma
Inhibition by interleukin 4 of leukemia inhibitory factor-, interleukin 6-, and dexamethasone-induced differentiation of mouse myeloid leukemia cells: role of c-myc and junB proto-oncogenes.
Cancer research 1994;54(2):592-7.
1993: Y Kanatani; Yoshio Honma; T Tsuchimochi; Junko Okabe-Kado; Naokazu Nagata; Kazuo Motoyoshi; M Hozumi
Induction of differentiation and growth suppression of myeloid leukemia cells by sera of patients with hematological disorders.
Anticancer research 1993;13(5C):1905-11.
1992: Takashi Kasukabe; Junko Okabe-Kado; Yoshio Honma; M Hozumi
Interleukin 4 potentiates the antiproliferative effect of 1 alpha, 25-dihydroxyvitamin D3 on mouse monocytic leukemia cells but antagonizes the antiproliferative effects of interferon alpha, beta and interleukin 6.
Leukemia research 1992;16(12):1191-6.
1992: Junko Okabe-Kado; Yoshio Honma; Takashi Kasukabe; M Hozumi
Synthesis of active metabolite(s) from 1 alpha-hydroxyvitamin D3 by human monocytic leukemia cells.
FEBS letters 1992;309(3):399-401.
1992: Yoshio Honma; Junko Okabe-Kado; Takashi Kasukabe; M Hozumi; H Kodama; S Kajigaya; T Suda; Y Miura
Herbimycin A, an inhibitor of tyrosine kinase, prolongs survival of mice inoculated with myeloid leukemia C1 cells with high expression of v-abl tyrosine kinase.
Cancer research 1992;52(14):4017-20.
1992: Junko Okabe-Kado; Takashi Kasukabe; Yoshio Honma; M Hayashi; W J Henzel; M Hozumi
Identity of a differentiation inhibiting factor for mouse myeloid leukemia cells with NM23/nucleoside diphosphate kinase.
Biochemical and biophysical research communications 1992;182(3):987-94.
1992: Junko Okabe-Kado
Factors inhibiting differentiation of myeloid leukemia cells.
Critical reviews in oncogenesis 1992;3(3):293-319.
1992: Takashi Kasukabe; Junko Okabe-Kado; Yoshio Honma; M Hozumi; T Matsuda; T Hirano
Characterization of growth inhibitory factors for mouse monocytic leukemia cells.
Leukemia research 1992;16(2):139-44.
1991: Takashi Kasukabe; Junko Okabe-Kado; Yoshio Honma; M Hozumi
Interleukin-4 inhibits the differentiation of mouse myeloid leukemia M1 cells induced by dexamethasone, D-factor/leukemia inhibitory factor and interleukin-6, but not by 1 alpha,25-dihydroxyvitamin D3.
FEBS letters 1991;291(2):181-4.
1991: Yoshio Honma; Y Onozuka; Junko Okabe-Kado; Takashi Kasukabe; M Hozumi
Hemin enhances the sensitivity of erythroleukemia cells to 1-beta-D-arabinofuranosylcytosine by both activation of deoxycytidine kinase and reduction of cytidine deaminase activity.
Cancer research 1991;51(17):4535-8.
1991: Yoshio Honma; Junko Okabe-Kado; Takashi Kasukabe; M Hozumi; S Kajigaya; T Suda; Y Miura
Induction by some protein kinase inhibitors of differentiation of a mouse megakaryoblastic cell line established by coinfection with Abelson murine leukemia virus and recombinant SV40 retrovirus.
Cancer research 1991;51(17):4649-55.
1991: Junko Okabe-Kado; M Hayashi; Yoshio Honma; M Hozumi; T Tsuruo
Inhibition by erythroid differentiation factor (activin A) of P-glycoprotein expression in multidrug-resistant human K562 erythroleukemia cells.
Cancer research 1991;51(10):2582-6.
1991: Junko Okabe-Kado; Yoshio Honma; M Hayashi; M Hozumi
Effects of transforming growth factor-beta and activin A on vitamin D3-induced monocytic differentiation of myeloid leukemia cells.
Anticancer research 1991;11(1):181-6.
1991: Junko Okabe-Kado; Yoshio Honma; M Hozumi
Inhibition by vitamin D3 of erythroid differentiation of human leukemia line cells induced by transforming growth factor beta or erythroid differentiation factor (activin A).
Leukemia research 1991;15(8):721-6.
1990: Y Honma; Junko Okabe-Kado; Takashi Kasukabe; M Hozumi; K Umezawa
Inhibition of abl oncogene tyrosine kinase induces erythroid differentiation of human myelogenous leukemia K562 cells.
Japanese journal of cancer research : Gann 1990;81(11):1132-6.
1990: M Hozumi; M Tomida; Yuri Yamamoto-Yamaguchi; Takashi Kasukabe; Junko Okabe-Kado; Yoshio Honma; M Hayashi
Protein factors that regulate the growth and differentiation of mouse myeloid leukaemia cells.
Ciba Foundation symposium 1990;148():25-33; discussion 33-42.
1989: Junko Okabe-Kado; Yoshio Honma; M Hayashi; M Hozumi
Inhibitory action of transforming growth factor-beta on induction of differentiation of myeloid leukemia cells.
Japanese journal of cancer research : Gann 1989;80(3):228-32.
1989: Yoshio Honma; Junko Okabe-Kado; M Hozumi; Y Uehara; S Mizuno
Induction of erythroid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity.
Cancer research 1989;49(2):331-4.
1989: M Hayashi; Junko Okabe-Kado; M Hozumi
A new experimental model for in vivo studies on differentiation and proliferation of leukemic cells using a mouse myeloid leukemia aneuploid line.
Leukemia research 1989;13(11):989-99.
1989: T Ikuta; Yoshio Honma; Junko Okabe-Kado; Takashi Kasukabe; M Hozumi
Normal mouse lung tissue produces a growth-inhibitory factor(s) preferential for mouse monocytic leukemia cells.
Cancer immunology, immunotherapy : CII 1989;30(3):139-44.
1988: Junko Okabe-Kado; Takashi Kasukabe; Yoshio Honma; M Hayashi; M Hozumi
Purification of a factor inhibiting differentiation from conditioned medium of nondifferentiating mouse myeloid leukemia cells.
The Journal of biological chemistry 1988;263(22):10994-9.
1988: Takashi Kasukabe; Junko Okabe-Kado; Yoshio Honma; M Hozumi
Purification of a novel growth inhibitory factor for partially differentiated myeloid leukemic cells.
The Journal of biological chemistry 1988;263(11):5431-5.
1988: M Hozumi; Yoshio Honma; Takashi Kasukabe; M Hayashi; Junko Okabe-Kado
Modification by vitamins and nutrients of induction of terminal differentiation of myeloid leukemia cells.
Progress in clinical and biological research 1988;259():131-48.
1987: Takashi Kasukabe; Junko Okabe-Kado; Yoshio Honma; M Hozumi
Production by undifferentiated myeloid leukemia cells of a novel growth-inhibitory factor(s) for partially differentiated myeloid leukemic cells.
Japanese journal of cancer research : Gann 1987;78(9):921-31.
1987: M Hayashi; Junko Okabe-Kado; M Hozumi
Establishment and characterization of a polyploid mouse myeloid leukemia cell line useful for in-vivo examination of cell proliferation kinetics.
Leukemia research 1987;11(11):1011-7.
1983: Y Honma; Takashi Kasukabe; Junko Okabe-Kado; M Hozumi; S Tsushima; H Nomura
Antileukemic effect of alkyl phospholipids. II. Prolongation of survival times of leukemic mice by alkyl ethyleneglycophospholipids.
Cancer chemotherapy and pharmacology 1983;11(2):77-9.
1983: Y Honma; Takashi Kasukabe; Junko Okabe-Kado; M Hozumi; S Tsushima; H Nomura
Antileukemic effect of alkyl phospholipids. I. Inhibition of proliferation and induction of differentiation of cultured myeloid leukemia cells by alkyl ethyleneglycophospholipids.
Cancer chemotherapy and pharmacology 1983;11(2):73-6.